KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to $351.0 million.

  • Boston Scientific's Capital Expenditures rose 2671.48% to $351.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $876.0 million, marking a year-over-year increase of 1088.61%. This contributed to the annual value of $876.0 million for FY2025, which is 1088.61% up from last year.
  • According to the latest figures from Q4 2025, Boston Scientific's Capital Expenditures is $351.0 million, which was up 2671.48% from $181.0 million recorded in Q3 2025.
  • Boston Scientific's 5-year Capital Expenditures high stood at $351.0 million for Q4 2025, and its period low was $75.0 million during Q1 2021.
  • For the 5-year period, Boston Scientific's Capital Expenditures averaged around $176.0 million, with its median value being $168.0 million (2024).
  • Within the past 5 years, the most significant YoY rise in Boston Scientific's Capital Expenditures was 11836.73% (2021), while the steepest drop was 2500.0% (2021).
  • Boston Scientific's Capital Expenditures (Quarter) stood at $266.0 million in 2021, then decreased by 20.3% to $212.0 million in 2022, then rose by 25.94% to $267.0 million in 2023, then increased by 3.75% to $277.0 million in 2024, then increased by 26.71% to $351.0 million in 2025.
  • Its Capital Expenditures stands at $351.0 million for Q4 2025, versus $181.0 million for Q3 2025 and $157.0 million for Q2 2025.